Onl Therapeutics

Onl Therapeutics company information, Employees & Contact Information

Explore related pages

Related company profiles:

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to helping patients see the future. Our mission is to develop innovative therapeutics to protect and improve the vision of patients with a range of retinal disease and conditions. By advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway, ONL is pioneering an entirely new approach to preserve sight. It is the first and only company focused on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss, a leading cause of blindness and an unaddressed medical need. ONL’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide Fas inhibitor designed to protect retinal cells from both death and inflammatory signaling pathways. ONL1204 Ophthalmic Solution is being developed for the treatment of retinal detachment, an acute condition for which the company has been granted orphan drug designation by the FDA. In addition, the company is currently developing ONL1204 in geographic atrophy associated with age-related macular degeneration, glaucoma, and other acute and chronic indications.

Company Details

Employees
42
Founded
-
Address
524 S Main St,
Phone
734-926-5530
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Ann Arbor, Michigan
Looking for a particular Onl Therapeutics employee's phone or email?

Onl Therapeutics Questions

News

ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD - Yahoo Finance

ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD Yahoo Finance

ONL Therapeutics randomizes first patient in phase 2 GALAXY trial evaluating xelafaslatide - Ophthalmology Times

ONL Therapeutics randomizes first patient in phase 2 GALAXY trial evaluating xelafaslatide Ophthalmology Times

Preventing Vision Loss: ONL Therapeutics’ David Esposito - The Healthcare Technology Report.

Preventing Vision Loss: ONL Therapeutics’ David Esposito The Healthcare Technology Report.

Johnson & Johnson backs UM spinout in $65M funding round - Crain's Detroit Business

Johnson & Johnson backs UM spinout in $65M funding round Crain's Detroit Business

ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing - Yahoo Finance

ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing Yahoo Finance

AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study - Business Wire

AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study Business Wire

Top Onl Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant